Korro Bio Inc. is an RNA editing company focused on the discovery and development of a new class of precision genetic medicines for both rare and highly prevalent diseases. Korro Bio Inc., formerly known as Frequency Therapeutics Inc., is based in LEXINGTON, Mass.
| Revenue (Most Recent Fiscal Year) | $6.39M |
| Net Income (Most Recent Fiscal Year) | $-117.26M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 32.22 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 2.61 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -1824.52% |
| Net Margin (Trailing 12 Months) | -1834.48% |
| Return on Equity (Trailing 12 Months) | -115.95% |
| Return on Assets (Trailing 12 Months) | -71.32% |
| Current Ratio (Most Recent Fiscal Quarter) | 6.90 |
| Quick Ratio (Most Recent Fiscal Quarter) | 6.90 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $5.46 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-5.32 |
| Earnings per Share (Most Recent Fiscal Year) | $-12.48 |
| Diluted Earnings per Share (Trailing 12 Months) | $-12.47 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 14.42M |
| Free Float | 13.76M |
| Market Capitalization | $205.95M |
| Average Volume (Last 20 Days) | 0.18M |
| Beta (Past 60 Months) | 3.20 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 4.60% |
| Percentage Held By Institutions (Latest 13F Reports) | 13.18% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |